Connect with us

Technology

Through an Investor Lens: ICI Paper Examines Tokenization in Asset Management

Published

4 hours ago

on

WASHINGTON, July 15, 2026 /PRNewswire/ — The tokenization of securities has evolved greatly over the past year, and a new paper from the Investment Company Institute (ICI), Tokenization: An Asset Management Perspective, examines the issue specifically through an asset management lens. The paper focuses on the implications and opportunities for registered funds and their investors.

ICI supports the responsible integration of tokenization into financial markets, provided that associated risks are managed prudently. Effective regulation should be fit-for-purpose, durable, and adaptable to technological innovation so that it encourages continued progress without compromising investor protection.

In order to advance the debate about the best way to integrate tokenization into regulated funds, ICI has conducted an impartial analysis of emerging models for the tokenization of funds and securities and their potential impact on a variety of aspects of fund operations, distribution, and regulation, identifying both potential benefits and concerns. 

ICI’s analysis focuses on two levels of potential impact: the tokenization of shares offered by investment funds, such as mutual funds and ETFs; and the tokenization of the assets in which investment funds invest on behalf of their investors. It also sets out principles for policymakers as they evaluate tokenization in capital markets and develop appropriate regulatory frameworks.

“Tokenization has the potential to change how investors access and experience financial markets, but innovation must be built on a strong foundation of investor protection,” said ICI President and CEO Eric J. Pan. “As policymakers consider this exciting technology, they should keep investors at the center and ensure that tokenization strengthens, rather than weakens, the protections that have long supported confidence in regulated funds.”

For more than 85 years, the Investment Company Act of 1940 has protected retail investors while evolving alongside capital markets. Tokenization presents another opportunity for that framework to evolve with new technology while maintaining its foundational protections.

“Fund regulations need to adapt to address advances in tokenization and blockchain technology,” said ICI General Counsel Paul Cellupica. “As tokenization models continue to develop, policymakers should ensure that securities laws apply clearly and consistently, while giving regulated funds room to innovate responsibly. The goal should be a regulatory framework that supports new market infrastructure without weakening investor safeguards that have long been at the core of successful regulated funds.”

Regulated funds have generated substantial benefits for investors, issuers, and the broader economy by directing capital to productive uses and helping investors participate in economic growth as they pursue their financial goals. ICI sees tokenization as a potential next chapter of that progress. As policymakers consider tokenization‘s role in capital markets, they should build on asset management’s enduring strengths and create the conditions for responsible innovation and continued progress.

Read ICI’s full paper here.

Contact: media@ici.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/through-an-investor-lens-ici-paper-examines-tokenization-in-asset-management-302826680.html

SOURCE Investment Company Institute

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Published

42 minutes ago

on

July 15, 2026

By

WASHINGTON, July 15, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar Series with Rahal Letterman Lanigan Racing.

The partnership aligns NEREUS’™ breakthrough innovation in motion relief with the high-speed world of IndyCar racing, where focus and stability are essential.

This sponsorship marks a symbolic milestone: 47 years since the last new motion sickness treatment was introduced in the United States. NEREUS™ represents a modern advancement as a selective NK-1 receptor antagonist designed to prevent vomiting induced by motion, offering a new option for millions who experience motion sickness during travel.

“Partnering with the No. 47 car perfectly captures this historic moment and our shared commitment to performance under challenging conditions,” said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda. 

The NEREUS™-branded No. 47 IndyCar will feature prominent sponsorship visibility across select NTT IndyCar Series events in 2026.

About NEREUS™ (tradipitant)

NEREUS™ is an oral NK-1 receptor antagonist FDA-approved for the prevention of vomiting induced by motion in adults. It is the first new pharmacologic treatment approved for this indication in over four decades.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

About Rahal Letterman Lanigan Racing

Rahal Letterman Lanigan Racing is a championship-winning team competing in the NTT IndyCar Series.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/nereus-powers-forward-sponsors-no-47-indycar-entry-celebrating-47-years-since-last-new-us-motion-sickness-treatment-302826721.html

SOURCE Vanda Pharmaceuticals Inc.

Continue Reading

Technology

VIAVI Announces Date for Fiscal Fourth Quarter and Fiscal Year 2026 Financial Results

Published

42 minutes ago

on

July 15, 2026

By

CHANDLER, Ariz., July 15, 2026 /PRNewswire/ — Viavi Solutions Inc. (VIAVI) (NASDAQ: VIAV) will announce its fiscal fourth quarter and fiscal year 2026 financial results for the period ended June 27, 2026, on Wednesday, August 5, 2026, after the close of market.

The Company will host an earnings call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the call and the replay will be available on the VIAVI website at https://investor.viavisolutions.com. The quarterly earnings press release, supplementary slides and historical financial tables will be posted under the “Quarterly Results” section.

To participate via telephone:

Toll-Free Dial-In Number:

1 (833) 461-5787

Toll Dial-In Number:

1 (585) 542-9983

Conference ID:

687 725 628

About VIAVI Solutions
VIAVI (NASDAQ: VIAV) is a global leader in test and measurement and optical technologies. Our test, monitoring, assurance, and resilient position, navigation and timing solutions enable and secure critical infrastructure ranging from data center ecosystems and communication networks to military, aerospace, railway and first responder communications. In addition, we develop and advance technologies used in high-volume optical applications across anti-counterfeiting, consumer electronics, aerospace, industrial and automotive end markets.

Learn more about VIAVI at www.viavisolutions.com. Follow us on VIAVI Perspectives, LinkedIn and YouTube.

Investors Contact:
Vibhuti Nayar, 408-404-6305; investor.relations@viavisolutions.com
Press Contact:
Amit Malhotra, 202-341-8624; amit.malhotra@viavisolutions.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/viavi-announces-date-for-fiscal-fourth-quarter-and-fiscal-year-2026-financial-results-302822275.html

SOURCE VIAVI Financials

Continue Reading

Technology

The American Council of the Blind to Distribute Ray-Ban Meta AI Glasses to Blind Veterans in St. Louis on July 27

Published

42 minutes ago

on

July 15, 2026

By

ALEXANDRIA, Va., July 15, 2026 /PRNewswire/ — The American Council of the Blind is proud to partner with Meta and the Blinded Veterans Association (BVA) to distribute Ray-Ban Meta AI glasses to eligible veterans who are blind during the upcoming 2026 ACB Conference and Convention in St. Louis.

The distribution will take place on Monday, July 27, from 1 to 5 p.m. CT at the Hyatt St. Louis at The Arch in downtown St. Louis. Eligible veterans can receive Ray-Ban Meta AI glasses at no cost while supplies last and a complimentary day pass to the ACB convention for July 27.

The initiative is part of Meta’s commitment to donate Ray-Ban Meta AI glasses to 130,000 blinded veterans worldwide, expanding access to technology that can support greater independence, access to information, and everyday tasks. As a distribution partner, ACB will also provide access to training resources for veterans receiving Meta glasses.

“Supporting veterans who are blind or have low vision has long been an important part of ACB’s mission,” said ACB Executive Director Scott Thornhill. “We are honored to partner with Meta and BVA to help connect veterans with innovative technology that can make a meaningful difference in their daily lives.”

Ray-Ban Meta AI glasses combine a lightweight, hands-free design with built-in artificial intelligence to help users complete everyday tasks more independently. Wearers can ask the glasses to describe their surroundings, read printed text, identify objects, and capture photos or videos.

To receive a pair of Ray-Ban Meta AI glasses at the July 27 distribution event, individuals must provide proof of military service, acknowledge legal blindness, and own a compatible smart phone.

A day pass to the ACB Conference and Convention with access to the Exhibit Hall will be available for recipients.

For more details about the Ray-Ban Meta AI glasses distribution, visit https://www.acb.org/glasses.

About the American Council of the Blind

The American Council of the Blind is a national member-driven consumer organization representing Americans who are blind or have low vision. With 65 affiliates, ACB strives to increase independence, security, equality of opportunity, and to improve the quality of life for all people who are blind or have low vision. For more information, visit https://www.acb.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-american-council-of-the-blind-to-distribute-ray-ban-meta-ai-glasses-to-blind-veterans-in-st-louis-on-july-27-302826844.html

SOURCE American Council of the Blind

Continue Reading

Trending